Whole body hyperthermia in adjuvant therapy of children with renal cell carcinoma

• Published in: Pediatric blood & cancer Vol. 44; no. 7; pp. 679 - 681
• Main Authors: Ismail-zade, Reiman S., Zhavrid, Edvard A., Potapnev, Michael P.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.06.2005; Wiley
• Subjects: Adenocarcinoma - therapy; Adenocarcinoma, Clear Cell - therapy; Adolescent; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Papillary - therapy; Carcinoma, Renal Cell - therapy; Chemotherapy, Adjuvant; Child; doxorubicin; Doxorubicin - administration & dosage; Female; General aspects; Humans; Hyperthermia, Induced; Interferon-alpha - administration & dosage; interferon-α; Kidney Neoplasms - therapy; Lymph Nodes - pathology; Male; Medical sciences; renal cell carcinoma; Tumors; whole body hyperthermia; Human; Kidney disease; Antineoplastic agent; DNA topoisomerase (ATP-hydrolysing); Pediatrics; Urinary system disease; Carcinoma; Enzyme; Cytokine; Adjuvant treatment; Enzyme inhibitor; Malignant tumor; Doxorubicin; renal cell carcinoma; Isomerases; Cancerology; interferon-a; whole body hyperthermia; Grawitz tumor; Anthracyclins; Interferon; Whole body; Child; Induced hyperthermia
• ISSN: 1545-5009; 1545-5017
• DOI: 10.1002/pbc.20299

Whole body hyperthermia (WBH) in combination with chemotherapy has been proven to be effective in some patients with advanced malignancies. However, only limited experience exists regarding the application of WBH with chemotherapy in children. We present the results of applying WBH and chemotherapy in five children with advanced renal cell carcinoma (RCC). WBH (3 hr, 41.8–42.5°C) combined with doxorubicin (50 mg/m2) and interferon‐α (3 MU/m2) were applied to patients after nephrectomy and lymph node dissection. Each patient received three to eight courses of treatment three times weekly. All children tolerated the combined therapy well without complications. Follow‐up of 7–68 months (median: 22 months) showed no tumor progression in patients with locoregional (n = 3) and metastatic (n = 2) disease. WBH with moderate dose doxorubicin and INF‐α might be a feasible treatment option in childhood RCC. Pediatr Blood Cancer 2005;44:679–681. © 2005 Wiley‐Liss, Inc.